Relapsing Multiple Sclerosis (RMS) Latest Advances

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Journal: Neurology

Published: December 15, 2025

Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 06, 2025

Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.

Journal: Neurology

Published: November 24, 2025

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

Journal: Neurology

Published: November 24, 2025

Differences in the Neural Substrate for Physical and Mental Quality of Life in Patients With Multiple Sclerosis.

Journal: Brain and behavior

Published: November 22, 2025

Cognitive training improves working memory, processing speed, and neural efficiency in multiple sclerosis.

Journal: Journal of clinical and experimental neuropsychology

Published: November 21, 2025

Comparison of methods for assessing the severity of multiple sclerosis based on a sample of patients from the Moscow region

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: November 19, 2025

Effect of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) on non-motor symptoms in multiple sclerosis: study protocol for a randomised, controlled trial.

Journal: BMJ open

Published: November 10, 2025

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 05, 2025

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 05, 2025

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Journal: JAMA network open

Published: November 03, 2025

Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 29, 2025

Filters

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?

Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?

Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.

Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

Differences in the Neural Substrate for Physical and Mental Quality of Life in Patients With Multiple Sclerosis.

Differences in the Neural Substrate for Physical and Mental Quality of Life in Patients With Multiple Sclerosis.

Cognitive training improves working memory, processing speed, and neural efficiency in multiple sclerosis.

Cognitive training improves working memory, processing speed, and neural efficiency in multiple sclerosis.

Comparison of methods for assessing the severity of multiple sclerosis based on a sample of patients from the Moscow region

Comparison of methods for assessing the severity of multiple sclerosis based on a sample of patients from the Moscow region

Effect of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) on non-motor symptoms in multiple sclerosis: study protocol for a randomised, controlled trial.

Effect of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) on non-motor symptoms in multiple sclerosis: study protocol for a randomised, controlled trial.

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.

Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.